Syncope in patients with an implantable cardioverter-defibrillator: incidence, prediction and implications for driving restrictions

Department of Cardiology/Angiology and Institute for Research in Arteriosclerosis, Westfalische Wilhelms-University, Munster, Germany.

OBJECTIVES: This retrospective study was undertaken to provide information on occurrence, risk prediction and prevention of syncope in patients with an implantable cardioverter-defibrillator (ICD). BACKGROUND: ICDs effectively terminate ventricular tachycardia and fibrillation (VT/VF). Incapacitating symptoms, such as syncope, may still occur. METHODS: We performed a retrospective analysis of data from 421 patients (clinical history, outpatient chart reviews and episode data) with mean (+/-SD) follow-up of 26 +/- 18 months. RESULTS: Of 421 patients, 229 (54.4%) had recurrent VT/VF, and 62 (14.7%) had syncope. The actuarial survival rate free of VT/VF was 58%, 45% and 37% and that for survival free of syncope was 90%, 85% and 81% at 12, 24 and 36 months after implantation, respectively. Once VT/VF had occurred, 76%, 68% and 62% of patients remained free of syncope during the following 12, 24 and 36 months, and 68%, 64% and 56% remained free of second syncope 12, 24 and 36 months after first syncope, respectively. In cases of syncope, the mean cycle length (CL) of VT was 251 +/- 56 ms. A low baseline left ventricular ejection fraction (LVEF), induction of fast VT (CL <300 ms) during programmed ventricular stimulation and chronic atrial fibrillation (AF) were associated with an increased risk of syncope. If the LVEF was >40%, fast VT had not been induced, and patients had no chronic AF; 96%, 92% and 92% of patients remained free of syncope after 12, 24 and 36 months, respectively. Once patients had a VT recurrence, syncope during the first VT and a high VT rate were the strongest risk predictors of future syncope. CONCLUSIONS: Identification of patients with an ICD with a low and high risk of syncope seems to be feasible and might help as a guide to driving restrictions in such patients.

This article has been cited by other articles:

				Task force members, J. Vijgen, G. Botto, J. Camm, C.-J. Hoijer, W. Jung, J.-Y. Le Heuzey, A. Lubinski, T. M. Norekval, M. Santomauro, et al. Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators Europace, August 1, 2009; 11(8): 1097 - 1107. [Abstract] [Full Text] [PDF]

				D. Bansch, H. Kottkamp, G. Gronefeld, J. Vogt, C. Israel, D. Bocker, G. Hindricks, K.-H. Kuck, and on behalf of the Quick-ICD investigators The quick-implantable-defibrillator trial Europace, December 1, 2007; 9(12): 1144 - 1150. [Abstract] [Full Text] [PDF]

				M. Abello and J. L. Merino Incidence of syncope after ICD implantation: low or high?: reply Eur. Heart J., October 2, 2006; 27(20): 2482 - 2482. [Full Text] [PDF]

				E. G. Moran and L. Mont Incidence of syncope after ICD implantation: low or high? Eur. Heart J., October 2, 2006; 27(20): 2481 - 2482. [Full Text] [PDF]

				M. Abello, J. L. Merino, R. Peinado, M. Gnoatto, M. A. Arias, M. Gonzalez-Vasserot, and J. A. Sobrino Syncope following cardioverter defibrillator implantation in patients with spontaneous syncopal monomorphic ventricular tachycardia Eur. Heart J., January 1, 2006; 27(1): 89 - 95. [Abstract] [Full Text] [PDF]

				E. Garcia-Moran, L. Mont, A. Cuesta, M. Matas, and J. Brugada Low recurrence of syncope in patients with inducible sustained ventricular tachyarrhythmias treated with an implantable cardioverter-defibrillator Eur. Heart J., June 1, 2002; 23(11): 901 - 907. [Abstract] [Full Text] [PDF]

				H. Binns and J. Camm Driving and arrhythmias BMJ, April 20, 2002; 324(7343): 927 - 928. [Full Text] [PDF]

				M. S. Wathen, M. O. Sweeney, P. J. DeGroot, A. J. Stark, J. L. Koehler, M. B. Chisner, C. Machado, and W. O. Adkisson Shock Reduction Using Antitachycardia Pacing for Spontaneous Rapid Ventricular Tachycardia in Patients With Coronary Artery Disease Circulation, August 14, 2001; 104(7): 796 - 801. [Abstract] [Full Text] [PDF]

				N. A. Freedberg, J. N. Hill, R. I. Fogel, E. N. Prystowsky, and the CARE Group Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy: Implications for antiarrhythmic therapy and driving restrictions J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1910 - 1915. [Abstract] [Full Text] [PDF]

				K. Glatter and L. B. Liem Implantable Cardioverter Defibrillator: Current Progress and Management Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2000; 4(3): 162 - 179. [Abstract] [PDF]

				D. Bansch, D. Bocker, J.u. Brunn, M. Weber, G.u. Breithardt, and M. Block Clusters of ventricular tachycardias signify impaired survival in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillators J. Am. Coll. Cardiol., August 1, 2000; 36(2): 566 - 573. [Abstract] [Full Text] [PDF]

				C.M Pratt, A.J Camm, J.T Bigger Jr, G Breithardt, R.W.F Campbell, A.E Epstein, L.J Kappenberger, K.-H Kuck, S Pocock, S Saksena, et al. Evaluation of antiarrhythmic drug efficacy in patients with an ICD. Unlimited potential or replete with complexity and problems? Eur. Heart J., November 1, 1999; 20(21): 1538 - 1552. [Abstract] [PDF]